1000 Mylan Boulevard
Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, Mylan innovates to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership
Founders: Milan Puskar, and Don Panoz
CEO: Heather Bresch
CFO: Neil Dimick
848 articles with Mylan
The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter to Evolus for its Biologics License Application (BLA) for DWP-450 (prabotulinumtoxinA), a drug to treat frown lines similar to Allergan’s Botox.
Shares of Perrigo have yet to rebound following the company’s weekend announcement that it expects the U.S. Food and Drug Administration to issue a Complete Response Letter for its generic version of Teva’s ProAir asthma inhaler.
Total revenues of $2.68 billion, down 1% compared to the prior year period.
According to Biosimilarpipeline, more than 660 companies worldwide have about 700 biosimilars in development.
Scandals are nothing new in any industry. The pharmaceutical and biotech industry are certainly no strangers to scandals – just ask convicted scandal-magnet Martin Shkreli.
At the end of 2016, there were an estimated 36.7 million people living with HIV across the globe. With a large and growing patient population, the market for HIV treatments is expected to grow to $22.5 billion by 2025.
Mylan Adds to Growing Women's Healthcare Portfolio with Launch of Generic for Oral Contraceptive Yaz®
Mylan Pharmaceuticals received final approval from the U.S. FDA for its Abbreviated New Drug Application for this product.
The FDA Giveth and Taketh Away: Grants Pfizer's MenB Breakthrough Therapy Designation and Turns D...
4/23/2018The FDA granted Pfizer’s Trumenba, a vaccine for meningococcal B disease in children ages one to nine years, Breakthrough Therapy Designation and declined to approve its biosimilar of Roche's Herceptin for breast cancer.
Mylan Rumored to be in Discussions to Buy Merck KGaA’s Consumer Health Business, but Mylan Denies It
4/13/2018Mylan is reportedly in top-level talks with Germany’s Merck KGaA to buy its consumer health business. However, Mylan has denied it.
Mylan Partners with Fujifilm Kyowa Kirin Biologics to Commercialize Biosimilar to Humira® (adalimumab)
Mylan acquires exclusive license to commercialize in Europe
Mylan Strengthens Its Capital Structure by Extending Its Debt Maturities with a Successful $1.5 Billion Bond Offering
The Notes will be issued by Mylan Inc. and guaranteed by Mylan N.V., and Mylan intends to use the net proceeds from the offering to redeem $1.5 billion aggregate principal amount of outstanding notes due in 2018 and 2019.
If a brand name drug loses patent protection, that often marks the date when companies can begin marketing generic versions of the drug. However, this has grown more complicated with the approvals of biosimilars.
Approval complements growing portfolio of cost-saving antiretroviral medications available to patients in the U.S.
Mylan and Biocon Receive Approvals from the European Commission and TGA Australia for Semglee™, Biosimilar Insulin Glargine
Mylan N.V. and Biocon Ltd. announced that their co-developed biosimilar insulin glargine Semglee™ has received marketing authorization approval from the European Commission (EC).
The U.S. Food and Drug Administration (FDA) approved Mylan NV’s Symfi (efavirnenz, lamivudine and tenofovir disoproxil fumarate) for adult and pediatric HIV-1 patients.This marks the third HIV approval for the company.
Mitomycin for Injection is available to Mylan's hospital and other institutional customers.
Here’s a look at eight biopharma companies with upcoming catalysts.
Hikma Pharmaceuticals generic version of Advair has hit a stumbling block with the FDA.
Quotidian Technical Highlights on Selected Generic Drugs Stocks -- Mallinckrodt, Momenta Pharma, Mylan, and Neurocrine Biosciences
WallStEquities.com is offering reports on MNK, MNTA, MYL, and NBIX which can be accessed for free by signing up to www.wallstequities.com/registration.
Mylan will launch Symfi Lo and Cimduo at a significant discount to the price of competing products to bring cost savings to the $20 billion U.S. ARV market